<DOC>
	<DOCNO>NCT01264783</DOCNO>
	<brief_summary>The objective study evaluate safety tolerability RNS60 administer intravenously healthy subject . 12 subject receive RNS60 placebo three escalate rate 48 hour rate .</brief_summary>
	<brief_title>Safety Tolerability RNS60 Given IV Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Males 1855 year Minimum body weight 60 kg BMI 1832 kg/m2 Able execute inform write consent A chronic acute disease might interfere evaluation safety RNS60 Current prior malignancy ( exclude history treat nonmelanoma skin carcinoma ) Positive viral serology test HBsAG , Hep C antibody , Hep A IgM , HIV Use prescription medication within 2 week first day dose Significant organ dysfunction , include cardiac , renal , liver , CNS , pulmonary , vascular , GI , endocrine metabolic Treatment monoclonal antibody therapy within 5 halflives prior first dose study medication Treatment investigational drug therapy within 30 day ( 5 halflives , whichever great ) prior first dose study medication Abnormal preadmission vital sign , physical exam , clinical laboratory , safety variable consider clinically significant population PI Subject consider scheduled surgical procedure participation study History alcohol and/or dug abuse within 1 year prior first dose study medication Subject donate plasma blood within 30 day prior first dose study medication Subject require treatment medication , either prescription nonprescription , include dietary supplement herbal medication , within 14 day prior first dose study medication . Exceptions nonprescription topical medication ( systemically absorb ) , acetaminophen , vitamin recommend daily dos ( mega dose vitamin ) A positive qualitative urine drug alcohol test Concurrent enrollment clinical trial Subject judge PI Medical Monitor inappropriate study Subject Gilbert 's syndrome Subject estimate creatinine clearance screen &lt; 90 mL/min .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>